Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company that develops and commercializes therapeutics for patients affected by kidney disease. The company focuses on addressing anemia and mineral metabolism disorders that arise as complications of chronic kidney disease. Its current portfolio consists of two approved oral products, Vafseo for anemia in dialysis patients and Auryxia for phosphorus control and iron deficiency anemia in dialysis and non dialysis dependent patients. In addition to its commercial products, Akebia maintains a pipeline of investigational agents that target rare kidney disorders such as focal segmental glomerulosclerosis, immunoglobulin A nephropathy, complement mediated glomerulopathy and lupus nephritis. The company also explores early stage hypoxia inducible factor modifiers for acute conditions like cardiac surgery related acute kidney injury and acute respiratory distress syndrome.

Akebia Therapeutics generates revenue primarily from the sale of Vafseo and Auryxia in the United States and from royalty and milestone payments under its licensing collaborations. Vafseo was launched in the United States in January 2025 and addresses an estimated $1 billion market for anemia treatment in dialysis patients based on current erythropoiesis stimulating agent pricing. Auryxia has been marketed since 2018 and historically contributed meaningful revenue before facing loss of exclusivity in March 2025 and anticipated generic competition thereafter. The company receives upfront payments, developmental milestones and tiered royalties from partners such as Medice for the European Economic Area, Tanabe Pharma Corporation for Japan and Asian markets, and CSL Vifor for the United States prior to the termination of that agreement. These collaborations provide additional cash flows and expand the geographic reach of its products without requiring direct commercial infrastructure in those territories.

Akebia Therapeutics positions itself as a leader in the kidney community by offering oral alternatives to injectable therapies that have long dominated anemia management. In the anemia market its main competitors include Amgen with epoetin alfa and Johnson & Johnson with darbepoetin alfa, as well as CSL Vifor which markets methoxy PEG epoetin beta and Roche which distributes similar agents outside the United States. In the phosphate binder market Auryxia competes with products from Sanofi such as Renagel and Renvela, with Fresenius Medical Care offerings like PhosLo and Velphoro, and with Shire’s Fosrenol. The company’s advantages stem from its hypoxia inducible factor platform that enables oral administration, its established supply and distribution agreements with the largest dialysis organizations serving the majority of patients, and its pipeline of novel mechanisms that address unmet needs in rare kidney diseases where few approved therapies exist.

Akebia Therapeutics serves dialysis patients, non dialysis dependent chronic kidney disease patients and the nephrologists who manage their care. The company’s products reach patients through contracts with major dialysis operators including DaVita Inc., Fresenius KidneyCare Group LLC, US Renal Care, Dialysis Clinic Inc. and Innovative Renal Care, which together provide care for 82% of the United States dialysis population. As of December 2025, approximately 290,000 dialysis patients in the United States had prescribing access to Vafseo through protocols established with these operators. Nephrologists prescribe Auryxia for non dialysis dependent patients with iron deficiency anemia, a group estimated to exceed 500,000 individuals in the United States. The company also works with health care providers to develop educational programs that support appropriate use of its therapies.